	US 12,239,627 B2
	Method of treating conditions related to the PGI2 receptor
Alan Glicklich, San Diego, CA (US)
Assigned to ARENA PHARMACEUTICALS, INC., New York, NY (US)
Filed by Arena Pharmaceuticals, Inc., New York, NY (US)
Filed on Oct. 20, 2023, as Appl. No. 18/491,524.
Application 17/227,740 is a division of application No. 16/870,777, filed on May 8, 2020, granted, now 11,000,500, issued on May 11, 2021.
Application 16/870,777 is a division of application No. 16/706,424, filed on Dec. 6, 2019, granted, now 10,688,076, issued on Jun. 23, 2020.
Application 16/706,424 is a division of application No. 15/520,864, granted, now 10,537,546, issued on Jan. 21, 2020, previously published as PCT/US2015/056824, filed on Oct. 22, 2015.
Application 18/491,524 is a continuation of application No. 17/863,098, filed on Jul. 12, 2022, granted, now 11,826,337.
Application 17/863,098 is a continuation of application No. 17/227,740, filed on Apr. 12, 2021, granted, now 11,426,377, issued on Aug. 30, 2022.
Claims priority of provisional application 62/067,916, filed on Oct. 23, 2014.
Prior Publication US 2024/0293353 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/325 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/33 (2006.01); A61P 9/12 (2006.01)

CPC A61K 31/325 (2013.01) [A61K 31/33 (2013.01); A61P 9/12 (2018.01); A61K 9/148 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01)]

11 Claims

1. A method for the treatment of pulmonary arterial hypertension (PAH) in a patient, the method comprising orally administering to the patient an optimized tolerated daily dose of 2-(((1r,4r)-4-(((4chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof,

wherein the optimized tolerated daily dose of Compound 1, or a pharmaceutically acceptable salt thereof, is obtained by using a titration scheme comprising:

initiating treatment at an initial daily administered dose that is equivalent to about 0.05 mg of Compound 1, and

weekly cycles of escalating the daily administered dose by a dose that is equivalent to about 0.05 mg of Compound 1 per day until the optimized tolerated daily dose of Compound 1, or a pharmaceutically acceptable salt thereof is reached;

wherein each dose of Compound 1, or a pharmaceutically acceptable salt thereof, is orally administered once daily.